title: Serum hepatocyte growth factor predicts ventricular remodeling following myocardial infarction.
abstract: Hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) stimulate endothelial cell proliferation and induce angiogenesis, but the timing and significance of their release in patients with acute myocardial infarction (AMI) are unknown in relation to future left ventricular remodeling. Venous blood samples were obtained at admission and up to 3 weeks later in 40 patients with AMI and in 40 age- and sex-matched control subjects. Blood samples were also taken from the coronary sinus (CS) in 20 patients on day 7 following AMI. Left ventricular end-diastolic volume in the subacute (1 week) and chronic (3 months) phases was assessed by left ventriculography to identify the remodeling group (n=15), which was defined as an increase in left ventricular end-diastolic volume index > or =5 ml/m(2) relative to the baseline value. Serum HGF and VEGF concentrations were higher in newly admitted patients with AMI than in the controls (HGF, 0.33 +/-0.09 vs 0.24+/-0.08 ng/ml, p<0.01; VEGF, 92.2+/-43.1 vs 67.2+/-29.8 pg/ml, p<0.01), peaking on day 7 (HGF, 0.41+/-0.12; VEGF, 161.7+/-76.9), and gradually decreasing between days 14 and 21. The HGF concentration in the CS did not differ from the concentration in the periphery, but the VEGF concentration was significantly more abundant in the CS than in the peripheral sample on day 7 (p<0.05). The serum HGF concentration on day 7 was higher in the remodeling group than in the nonremodeling group (0.47 +/-0.13 vs 0.36+/-0.09 ng/ml, p<0.01), but there was no difference between the groups on admission, day 14 and day 21. The serum VEGF concentration did not differ between the remodeling and nonremodeling groups at any time. Thus, the serum HGF concentration on day 7 after AMI is mostly from noncardiac sources and predicts left ventricular remodeling.
authors.affiliation: Department of Cardiology and Clinical Research, National Zentsuji Hospital, Japan. tsoeki@ri.ncvc.go.jp
authors.forename: Takeshi
authors.initials: T
authors.lastname: Soeki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Tamura
authors.forename: Hisanori
authors.initials: H
authors.lastname: Shinohara
authors.forename: Koichi
authors.initials: K
authors.lastname: Sakabe
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Onose
authors.forename: Nobuo
authors.initials: N
authors.lastname: Fukuda
mesh_terms: D000368:Aged; D003326:Coronary Circulation; D016228:Endothelial Growth Factors / Q000097:blood / Q000502:physiology; D005260:Female; D017228:Hepatocyte Growth Factor / Q000097:blood* / Q000502:physiology; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood / Q000502:physiology; D008222:Lymphokines / Q000097:blood / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000503:physiopathology*; D011237:Predictive Value of Tests; D013318:Stroke Volume; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016277:Ventricular Function, Left; D020257:Ventricular Remodeling
chemical_list: D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D017228:Hepatocyte Growth Factor